Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antidepressant |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA 2013 |
| gptkbp:ATCCode |
N06AX26
|
| gptkbp:CASNumber |
508233-74-7
|
| gptkbp:chemicalFormula |
C18H22N2S
|
| gptkbp:contraindication |
concurrent use with MAOIs
|
| gptkbp:developedBy |
gptkb:Takeda
gptkb:Lundbeck |
| gptkbp:eliminationHalfLife |
66 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vortioxetine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Brintellix
gptkb:Trintellix |
| gptkbp:mechanismOfAction |
norepinephrine reuptake inhibitor
serotonin modulator and stimulator |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
298.45 g/mol
|
| gptkbp:patentExpiryUS |
2026
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:proteinBinding |
98%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting constipation dizziness sexual dysfunction |
| gptkbp:usedFor |
gptkb:major_depressive_disorder
|
| gptkbp:bfsParent |
gptkb:Antidepressants
|
| gptkbp:bfsLayer |
6
|